Prognostic significance of recurrent additional chromosomal abnormalities in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

被引:10
作者
Seol, Chang Ahn [1 ,2 ]
Cho, Young-Uk [1 ,2 ]
Jang, Seongsoo [1 ,2 ]
Park, Chan-Jeoung [1 ,2 ]
Lee, Jung-Hee [2 ,3 ]
Lee, Je-Hwan [2 ,3 ]
Lee, Kyoo Hyung [2 ,3 ]
Seo, Eul-Ju [1 ,2 ]
机构
[1] Univ Ulsan, Coll Med, Dept Lab Med, Seoul, South Korea
[2] Asan Med Ctr, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Dept Internal Med, Seoul, South Korea
关键词
Acute lymphoblastic leukemia; Philadelphia chromosome-positive; additional hromosomal abnormality; prognosis; CHILDRENS ONCOLOGY GROUP; CYTOGENETIC ABNORMALITIES; IMPACT; CHEMOTHERAPY;
D O I
10.1016/j.cancergen.2017.06.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL), additional chromosomal abnormalities (ACAs) are frequently observed. We investigated the cytogenetic characteristics and prognostic significance of ACAs in Ph-positive ALL. We reviewed the clinical data and bone marrow cytogenetic findings of 122 adult Ph-positive ALL patients. The ACAs were examined for partial or whole chromosomal gains or losses, and structural aberrations. The overall survival (OS) and disease-free survival (DFS) of patients who received hematopoietic cell transplantation were compared between the isolated Ph group and ACA group. ACAs were present in 73.0% of all patients. The recurrent ACAs were extra Ph (24.7%), 9/9p loss (20.2%), and 7/7p loss (19.1%). Complex karyotype was found in 28.1% of patients in the ACA group. Younger patients (19-30 years) in the ACA group showed the highest frequency of extra Ph (54%) compared to other age groups. The OS in the ACA group was significantly shorter than in the isolated Ph group. The presence of an extra Ph chromosome or 9/9p loss was significantly associated with shorter OS and DFS, whereas 7/7p loss and complex karyotype were not associated with poorer prognosis. We suggest that subclassification of ACAs could be applied to prognostic investigation of Ph-positive ALL.
引用
收藏
页码:29 / 36
页数:8
相关论文
共 50 条
[41]   Comparison of autologous and allogeneic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia [J].
Lyu, Mengnan ;
Jiang, Erlie ;
He, Yi ;
Yang, Donglin ;
Ma, Qiaoling ;
Pang, Aiming ;
Zhai, Weihua ;
Wei, Jialin ;
Huang, Yong ;
Zhang, Guixin ;
Zhang, Rongli ;
Feng, Sizhou ;
Han, Mingzhe .
HEMATOLOGY, 2021, 26 (01) :65-74
[42]   Managing Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitors [J].
Ravandi, Farhad .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (02) :198-203
[43]   Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [J].
Mathisen, Michael S. ;
O'Brien, Susan ;
Thomas, Deborah ;
Cortes, Jorge ;
Kantarjian, Hagop ;
Ravandi, Farhad .
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (03) :187-194
[44]   Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults: Current Treatments and Future Perspectives [J].
Yilmaz, Musa ;
Kantarjian, Hagop ;
Ravandi-Kashani, Farhad ;
Short, Nicholas J. ;
Jabbour, Elias .
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) :216-223
[45]   Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults [J].
Brattas, Marte Karen ;
Reikvam, Hakon ;
Tvedt, Tor Henrik Anderson ;
Bruserud, Oystein .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (05) :411-420
[46]   PONATINIB FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA AND PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA [J].
Narayanan, V. ;
Pollyea, D. A. ;
Gutman, J. A. ;
Jimeno, A. .
DRUGS OF TODAY, 2013, 49 (04) :261-269
[47]   A prognostic approach on a case of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia with monosomy-7 [J].
Skhoun, Hanaa ;
Khattab, Mohammed ;
Belkhayat, Aziza ;
Chebihi, Zahra Takki ;
Dakka, Nadia ;
El Baghdadi, Jamila .
CLINICAL CASE REPORTS, 2021, 9 (12)
[48]   Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia [J].
Snyder, DS .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2000, 6 (06) :597-603
[49]   Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia [J].
Stock, Wendy ;
Martinelli, Giovanni ;
Stelljes, Matthias ;
DeAngelo, Daniel J. ;
Goekbuget, Nicola ;
Advani, Anjali S. ;
O'Brien, Susan ;
Liedtke, Michaela ;
Merchant, Akil A. ;
Cassaday, Ryan D. ;
Wang, Tao ;
Zhang, Hui ;
Vandendries, Erik ;
Jabbour, Elias ;
Marks, David, I ;
Kantarjian, Hagop M. .
CANCER, 2021, 127 (06) :905-913
[50]   Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy [J].
Ohno R. .
Current Hematologic Malignancy Reports, 2006, 1 (3) :180-187